Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Why Is Blueprint Medicines (BPMC) Down 11.4% Since Last Earnings Report?
12:48pm, Thursday, 02'nd Jun 2022
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022
02:08pm, Wednesday, 01'st Jun 2022 Benzinga
Upgrades
Citigroup upgraded the previous rating for FinVolution Group (NYSE:FINV) from Neutral to Buy. FinVolution Gr earned $0.30 in the first quarter, compared to $0.31 in the year-ago quarter. The
10 Biggest Price Target Changes For Wednesday
11:34am, Wednesday, 01'st Jun 2022 Benzinga
Keybanc cut Ambarella, Inc. (NASDAQ: AMBA) price target from $160 to $120. Ambarella shares fell 5% to $81.00 in pre-market trading.
Piper Sandler reduced Salesforce, Inc. (NYSE: CRM) price target
What 3 Analyst Ratings Have To Say About Blueprint Medicines
03:32pm, Thursday, 19'th May 2022 Benzinga
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
2
0
0
L
3 Small-Caps That Might Be Acquisition Candidates
08:00pm, Monday, 09'th May 2022 The Motley Fool
Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.
Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark
05:22pm, Wednesday, 04'th May 2022 Zacks Investment Research
Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.
Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark
03:03pm, Wednesday, 04'th May 2022
Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.
Blueprint Medicines Corporation (BPMC) CEO Kate Haviland on Q1 2022 Results - Earnings Call Transcript
01:10pm, Tuesday, 03'rd May 2022
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland -
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
01:01pm, Tuesday, 03'rd May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis
The FDA's Psychopharmaco
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
12:35pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 0% and 45.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Where Blueprint Medicines Stands With Analysts
06:03pm, Wednesday, 13'th Apr 2022 Benzinga
Over the past 3 months, 6 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with understandi
2 Under-the-Radar Biotech Stocks to Buy in 2022
03:30pm, Monday, 11'th Apr 2022 The Motley Fool
Both companies have catalysts for explosive growth this year.
2 Under-the-Radar Biotech Stocks to Buy in 2022
11:30am, Monday, 11'th Apr 2022
Both companies have catalysts for explosive growth this year.
7 Biotech Stocks to Buy With Key Catalysts for April
06:59am, Tuesday, 05'th Apr 2022
Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies bel
Blueprint Medicines (BPMC) Gets EU Nod for Ayvakyt in SM
04:19pm, Monday, 28'th Mar 2022 Zacks Investment Research
The European Commission approves Blueprint Medicines' (BPMC) Ayvakyt for treating adult patients with advanced systemic mastocytosis.
